Paxlovid effective treatment in symptomatic pregnant women with SARS-CoV-2 Omicron variant infection

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-11-15 10:00 GMT   |   Update On 2023-11-15 10:01 GMT
Advertisement

Nirmatrelvir/ritonavir is an effective treatment in symptomatic pregnant women with SARS-CoV-2 Omicron variant infection suggests a new study published in the Nature Medicine.

A study was done to date there is a lack of randomized trial data examining the use of the antiviral nirmatrelvir/ritonavir in SARS-CoV-2-infected pregnant persons. This target trial emulation study aims to address this gap by evaluating the use of nirmatrelvir/ritonavir in non-hospitalized pregnant women with symptomatic SARS-CoV-2 Omicron variant infection. Among patients diagnosed between 16th March 2022 and 5th February 2023, exposure was defined as outpatient nirmatrelvir/ritonavir treatment within five days of symptom onset or COVID-19 diagnosis.

Primary outcomes were maternal morbidity and mortality index (MMMI), all-cause maternal death, and COVID-19-related hospitalization, while secondary outcomes were individual components of MMMI, preterm birth, stillbirth, neonatal death, and caesarean section. One-to-ten propensity-score matching was conducted between nirmatrelvir/ritonavir users and non-users; followed by cloning, censoring, and weighting. Overall, 211 pregnant women on nirmatrelvir/ritonavir and 1,998 non-users were included. Nirmatrelvir/ritonavir treatment was associated with reduced 28-day MMMI risk (absolute risk reduction [ARR] = 1.47%, 95%CI = 0.21%-2.34%); but not 28-day COVID-19-related hospitalization (ARR = -0.09%, 95%CI = -1.08%-0.71%).

Nirmatrelvir/ritonavir treatment was also associated with reduced risks of caesarean section (ARR = 1.58%, 95%CI = 0.85%-2.39%); and preterm birth (ARR = 2.70%, 95%CI = 0.98%-5.31%). No events of maternal or neonatal death or stillbirth were recorded. The findings suggest nirmatrelvir/ritonavir is an effective treatment in symptomatic pregnant women with SARS-CoV-2 Omicron variant infection.


Reference:

Wong, C.K.H., Lau, K.T.K., Chung, M.S.H. et al. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation. Nat Med (2023). https://doi.org/10.1038/s41591-023-02674-0

Keywords:

Wong, C.K.H., Lau, K.T.K., Chung,. Nirmatrelvir/ritonavir, use, pregnant, women, SARS-CoV-2, Omicron, infection, target, trial, emulation, Nat Med



Tags:    
Article Source : Nature Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News